Editorial: Novel preclinical model, biomarker, treatment and drug delivery to address immune evasion in cancer.
作者信息
Mai Chun-Wai, Macek Jilkova Zuzana, Dua Kamal, Goh Bey-Hing
机构信息
Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia.
Univ. Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.
出版信息
Front Immunol. 2024 Sep 13;15:1486819. doi: 10.3389/fimmu.2024.1486819. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Novel preclinical model, biomarker, treatment and drug delivery to address immune evasion in cancer.
Front Immunol. 2024 Sep 13;15:1486819. doi: 10.3389/fimmu.2024.1486819. eCollection 2024.
2
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9.
3
Mechanisms of immune escape in the cancer immune cycle.
Int Immunopharmacol. 2020 Sep;86:106700. doi: 10.1016/j.intimp.2020.106700. Epub 2020 Jun 23.
4
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
Cancer Res. 2020 Oct 1;80(19):4037-4041. doi: 10.1158/0008-5472.CAN-20-1420. Epub 2020 Jun 18.
5
Acquired resistance to cancer immunotherapy.
Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.
6
Translational Control of Immune Evasion in Cancer.
Trends Cancer. 2021 Jul;7(7):580-582. doi: 10.1016/j.trecan.2021.04.002. Epub 2021 May 7.
7
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Front Immunol. 2021 Dec 6;12:789473. doi: 10.3389/fimmu.2021.789473. eCollection 2021.
8
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
Cells. 2024 May 17;13(10):864. doi: 10.3390/cells13100864.
9
Editorial: Understanding convergent evasion mechanisms in cancer and chronic infection: implications for immunotherapy.
Front Immunol. 2024 Jul 1;15:1450555. doi: 10.3389/fimmu.2024.1450555. eCollection 2024.
10
Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
Clin Immunol. 2009 Jan;130(1):34-40. doi: 10.1016/j.clim.2008.08.020. Epub 2008 Nov 13.
本文引用的文献
1
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.
Br J Cancer. 2024 Aug;131(3):420-429. doi: 10.1038/s41416-024-02684-w. Epub 2024 May 17.
2
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
J Transl Med. 2023 Nov 6;21(1):786. doi: 10.1186/s12967-023-04673-8.
3
Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.
Cell Biol Toxicol. 2023 Dec;39(6):2501-2526. doi: 10.1007/s10565-023-09830-9. Epub 2023 Sep 27.
4
Modeling prostate cancer: What does it take to build an ideal tumor model?
Cancer Lett. 2022 Sep 1;543:215794. doi: 10.1016/j.canlet.2022.215794. Epub 2022 Jun 17.
5
Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion.
Cancers (Basel). 2020 Jul 11;12(7):1872. doi: 10.3390/cancers12071872.
Zotero 插件